The goal of this clinical trial is to assess whether a seven-day course of standard of care (echinocandin) antifungal therapy is non-inferior to a 14-day course of echinocandin antifungal therapy in patients with uncomplicated candidemia in terms of clinical, mycologic, adverse events and all cause mortality.
Patients ≥ 18 years of age
Uncomplicated candidemia (positive blood culture only). No evidence of invasive candidiasis at day 1 or until day 7.
Received < 5 days of prior antifungal therapy
Informed Consent for randomization
Inadequate source control (e.g., unable to remove endovascular devices, urinary catheters).
Invasive candidiasis of any type (e.g., deep seated candidiasis from sources other than blood)
Abnormal LFTs > 10-fold
Greater than 5 days of prior antifungal therapy
Participants will be recruited from: A. Inpatient settings based on positive blood cultures for candidemia. B. Daily review of microbiology labs C. Referrals from investigators, ICUs and hospital unit personnel
Cohort
Prospective
Antifungal treatment
DrugShort-course antifungal therapy (7 days) versus standard of care antifungal therapy (14 days)
Eradication of candida from the blood at day 7 or day 14
Blood culture monitoring at day 7 and day 14
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
